×

Biogen brawl

Tuesday, 22 Dec 2015 | 4:43 PM ET

Michael Yee, RBC Capital Markets, has a $450 price target on Biogen and Andrew McDonald, co-portfolio manager of Bioshares fund, says Biogen is the best short in Biotech.